Literature DB >> 10805964

Evidence of type II estrogen receptor in human osteoblast-like cells.

A Toesca1, A Pagnotta, N Specchia.   

Abstract

Osteoblast-like cells isolated from human bone bioptic specimens were characterized and analysed for the presence of type II estrogen receptor (type II EBS). The amount of type II EBS was measured by a whole-cell assay at 4 degrees C for 2.5 h using [(3)H]-estradiol as tracer. Saturation analysis, used to investigate the binding characteristic of type II EBS, resulted in a sigmoid curve. Scatchard analysis showed the binding affinity of the estrogen receptor, yielding a concave plot. The dissociation constant (K(d)), determined from the [(3)H]-estradiol concentration required for half saturation was about 12+/-2 nM (SD). The number of type II EBS, estimated at maximum binding, was 197,000+/-8800 sites per cell. If the regulation of the receptor by flavonoids would be confirmed, the evidence of type II EBS in osteoblast-like cells could suggest a direct action of ipriflavone and others flavonoids on bone density in postmenopausal osteoporosis. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10805964     DOI: 10.1006/cbir.2000.0509

Source DB:  PubMed          Journal:  Cell Biol Int        ISSN: 1065-6995            Impact factor:   3.612


  2 in total

1.  Participation of estrogen receptors in the enhancement of osteoblast differentiation by TAK-778.

Authors:  Márcio Mateus Beloti; Larissa Sverzut Bellesini; Paulo Tambasco de Oliveira; Adalberto Luiz Rosa
Journal:  Mol Cell Biochem       Date:  2006-02-14       Impact factor: 3.396

2.  Expression and localization of estrogen receptor-beta in annulus cells of the human intervertebral disc and the mitogenic effect of 17-beta-estradiol in vitro.

Authors:  Helen E Gruber; Dean Yamaguchi; Jane Ingram; Kelly Leslie; Weibiao Huang; Timothy A Miller; Edward N Hanley
Journal:  BMC Musculoskelet Disord       Date:  2002-01-17       Impact factor: 2.362

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.